explore -WSS

explore

author：hotspot 2025-09-29 12:30:32 - browse：112

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after raising the largest Series A round in the industry this year.

ReNAgade launched in May with hopes of becoming a one-stop shop for medicines targeting RNA, the genetic blueprints that cells use to make proteins instrumental in numerous diseases. These types of medicines are in high demand following the advent of mRNA vaccines for Covid and RNA-silencing therapies made by companies like Alnylam Pharmaceuticals.

ReNAgade was able to capitalize on that excitement when it raised a $300 million Series A round led by MPM Capital’s BioImpact Capital and F2 Ventures. But in recent days, the company decided to lay off around 10% of its 100-person team, according to a company statement and former employees’ posts on social media.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： In Spain, a hospital brews its own CAR

WSS

The United States is paying nearly triple for new Covid vaccines

With Roe v Wade overturned, abortion providers work to adapt

Why health records don't always know when patients are dead

Three trends to watch in biotech in 2024

Health insurers' Q3 question: how much care are people getting?

In Spain, a hospital brews its own CAR

entertainment

explore

hotspot

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

ChatGPT in medicine: STAT answers readers' burning questions

Experts study whether long Covid risk adds up with each reinfection

Medicare details structure of new drug price negotiation program

Bristol Myers buys into radiopharmaceuticals with RayzeBio

Psychedelics group wrestles with new pharma identity

Will an HIV vaccine ever be a reality?

Tori Bowie and the unacceptable rates of Black maternal death

Study points to new risk in gene therapy death of Terry Horgan

focus

What STAT readers think about the FDA and patient advocacy

Can sheer will power keep patients alive in their dying hours?

Can sheer will power keep patients alive in their dying hours?

CRISPR gene editing developments we’re watching in 2024

With Roe v Wade overturned, abortion providers work to adapt

SEC charges former device maker CEO with $41 million fraud

focus

focus

focus

focus